Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-24

Doing some reading about the scientific sessions at the AHA conference. All info is taken from the selection criteria on the AHA website.

"Guidelines for Late-Breaking Science Presentations
Late-Breaking Science sessions are innovative and provide the latest breakthroughs in clinical science. These sessions provide notable exposure and recognition for studies likely to have a significant impact on clinical practice and/or to make significant advances in a scientific field."

- I don't see how negative results would be accepted under these criteria

"Simultaneous Journal Publication of Clinical Trials: Simultaneous publication of Clinical Trials is acceptable and encouraged as long as the embargo policies of the AHA and the involved journals are coordinated. If a clinical trial has been submitted to and accepted for publication, the presenter is responsible for insuring that the journal editor respects the AHA publication embargo policy. Publication of a clinical trial either in print or on a journal web site prior to presentation at Sessions will necessitate withdrawal of the trial from the program."

- I guess this means we won't hear any more results until after the conference.

The document also mentions that the abstract will be published in Circulation - For those unaware of the significance of this journal it is possibly the most respected cardiology journal going around. Overall the fact that this trial has been given 10min to present at such a major conference AND has had an abstract accepted for publication in circulation says that these results are at the very least thought provoking and possibly ground breaking.

That said, keep in mind that this is not a phase 3 trial and therefore is not grounds to PROVE success of the treatment. However it may indicate a likely positive phase 3 trial in the future.

All good news despite today wiping 15% off the SP. Good luck in the coming months everyone.